Shu-Yen Ho

Efficacy and Safety of Fluticasone Propionate/Salmeterol HFA 134A MDI in Patients with Mild‐to‐Moderate Persistent Asthma

P. Dorinsky, D. Peden, C. Scott, 2004, The Journal of asthma : official journal of the Association for the Care of Asthma.

A note on sample size savings with the use of a single well‐controlled clinical trial to support the efficacy of a new drug

P. Darken, Shu-Yen Ho, 2004 .

Addition of a 5-lipoxygenase-activating protein inhibitor to an inhaled corticosteroid (ICS) or an ICS/long-acting beta-2-agonist combination in subjects with asthma

N. Snowise, D. Clements, Shu-Yen Ho, 2013, Current medical research and opinion.

Effects of fluticasone propionate and salmeterol hydrofluoroalkane inhalation aerosol on asthma-related quality of life.

H. Ortega, C. Scott-Wilson, L. Schoaf, 2009, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Sparse matrix methods for unbalanced multifactor analysis of variance and covariance

J. Klotz, Shu-Yen Ho, 1992 .

Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study

N. Snowise, C. Ambery, K. Smart, 2013, Respiratory Research.

PROPERTIES OF MULTIPLE INTERSECTION-UNION TESTS FOR MULTIPLE ENDPOINTS IN COMBINATION THERAPY TRIALS

Peter H. Westfall1*, Shu-Yen Ho, Barbara A. Prillaman, 2001, Journal of biopharmaceutical statistics.